GeoVax Labs, Inc. (Nasdaq: GOVX) announced a strategic shift to concentrate resources on its lead programs, GEO-MVA and Gedeptin, while discontinuing development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, based on the evolving global COVID-19 vaccine market, allows the company to focus on programs with clearer regulatory pathways and stronger commercialization potential.
GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine targeting mpox and smallpox, is advancing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. The program aims for approval based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, potentially accelerating timelines and reducing clinical risk. Clinical-grade material is already manufactured, and the company plans to initiate a Phase 3 trial in the second half of 2026. GeoVax has initiated outreach with global procurement and preparedness stakeholders, including government agencies and international organizations, to support potential vaccine supply agreements for national stockpiling and outbreak response.
Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform, is being advanced in oncology, particularly in head and neck cancers. The planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting, aiming to enhance tumor immune visibility. Gedeptin's mechanism generates a potent chemotherapeutic agent locally within tumors, sensitizing them to checkpoint inhibitors and potentially improving response rates. This aligns with emerging immuno-oncology treatment paradigms, such as the KEYNOTE-689 trial demonstrating improved event-free survival with neoadjuvant checkpoint inhibitor therapy.
David Dodd, Chairman and CEO of GeoVax, stated, “GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value.” He emphasized that as GEO-MVA advances toward clinical validation and commercialization, and as Gedeptin gains relevance, the company is aligning resources for focused execution.
GeoVax maintains a global intellectual property portfolio and continues to evaluate strategic partnerships and funding opportunities. The company's decision to discontinue the COVID-19 vaccine was not based on safety concerns but on market dynamics. For more information, visit www.geovax.com.